Use the hyperlinks, where available to access additional clinical trial information.
An International Investigator-led Phase III Multi Arm Multi Stage Multi-centre Randomised Controlled Platform Trial of Adjuvant Therapy in Patients With Resected Primary Renal Cell Carcinoma (RCC) at High or Intermediate Risk of Relapse
Australian & New Zealand Urogenital and Prostate Cancer Trials Group Limited (ANZUP)
Other Non-Commercial Sponsor
University College London Hospitals
This trial comprises of three different arms. Participants randomly assigned to the first arm (Arm A) will be actively monitored for 1-year, in line with current standard-of-care practice in people with resected primary renal cell carcinoma (RCC) at high- or intermediate- risk of relapse. Participants randomly allocated to the second arm (Arm B) will receive durvalumab (1500mg) every 4 weeks for 1-year (up to 13 cycles). Participants randomly allocated to the third arm (Arm C) will receive durvalumab (like those in Arm B) and tremelimumab (75mg) on day 1 and week 4 visits.